Steven Schuster, MD
Hematology & Oncology · Fort Collins, CONPI 1467664136
Payments from drug & device makers
Across 979 payments — averaging $8621.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4.6M
- Seagen Inc.$1.4M
- Novartis$520K
- Eli Lilly$474K
- Janssen Research & Development, LLC$389K
- Incyte Corporation$120K
- plus $958K from 24 others
Across 10 payments — averaging $1299.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$7K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 206 | $4,594,425 |
| Seagen Inc. | 200 | $1,384,132 |
| Novartis | 6 | $519,656 |
| Eli Lilly | 9 | $474,162 |
| Janssen Research & Development, LLC | 111 | $389,373 |
| Incyte Corporation | 105 | $120,397 |
| Regeneron | 21 | $113,971 |
| Astrazeneca UK Limited | 1 | $103,338 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $81,541 |
| Pharmacyclics LLC, An Abbvie Company | 67 | $71,079 |
| Karyopharm Therapeutics Inc. | 32 | $63,897 |
| AstraZeneca | 1 | $62,362 |
| Johnson & Johnson(2 entities) | 51 | $61,667 |
| Beone Medicines USA, Inc. | 16 | $59,292 |
| Beigene USA, Inc. | 11 | $56,332 |
| EMD Serono, Inc. | 12 | $51,762 |
| Genentech USA, Inc. | 39 | $50,732 |
| AbbVie | 34 | $47,222 |
| Merck | 2 | $42,959 |
| E.r. Squibb & Sons, L.L.C. | 9 | $30,335 |
| Bristol Myers Squibb | 4 | $26,423 |
| Genmab U.S., Inc. | 14 | $21,599 |
| Genentech, Inc. | 3 | $12,260 |
| ADC Therapeutics America, Inc. | 1 | $1,400 |
| Jazz Pharmaceuticals Inc. | 1 | $103 |
| Novo Nordisk | 1 | $26 |
| Adaptive Biotechnologies Corporation | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Gilead | 1 | $20 |
| Myovant Sciences Inc. | 1 | $13 |
How this compares
$8,440,519 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Fort Collins
- David AndorskyBoulder$31.5M
- John BurkeAurora$25.4M
- Elena ShagisultanovaAurora$22.4M
- Allen CohnDenver$13.5M
- Elaine LamAurora$12.6M
- Robert RifkinDenver$11.3M
- Robert JotteLone Tree$9.4M
- Daniel PollyeaAurora$9.4M
- Henning SchadeDenver$9M
- Manali KamdarAurora$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.